TYK2-selective kinase inhibitor (JH1 domain)

in Ph. II for inflamm. conditions (oral, QD)

from structure-based design

J. Med. Chem., Aug. 5, 2020

Pfizer, Cambridge, MA / Groton, CT

Structure of Ropsacitinib (PF-06826647)

PF-06826647 is a TYK2-selective kinase inhibitor which binds to the catalytically active JH1 kinase domain, in contrast to BMS-986165, a TYK2 inhibitor in Ph. III for psoriasis that binds to…

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: